39
Participants
Start Date
May 5, 2021
Primary Completion Date
June 17, 2022
Study Completion Date
October 5, 2022
NX-13 250mg IR
Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.
NX-13 500mg IR
Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.
NX-13 500mg MR
Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.
Placebo
Subjects will take study drug by ingesting one tablet per day, recommended at the same time in the morning for consistency. Subjects in a NX-13 group will receive either 250 mg or 500 mg of NX-13 in an immediate release or modified release tablet and subjects in the placebo group will receive matched placebo.
Communal Non-commercial Enterprise O.F. Herbachevskyi Regional Clinical Hospital of Zhytomyr Regional Council, Zhytomyr
Care Access, New York
Care Access, Pottsville
Communal Non-Commercial Enterprise of M.I. Pyrohov Vinnytsia Regional Clinical Hospital of Vinnytsia Regional Council, Vinnytsia
Communal Non-commercial Enterprise Vinnytsia City Clinical Hospital #1, Department of Gastroenterology, Vinnytsia
Care Access, Lumberton
Atlanta Center for Gastroenterology, P.C., Decatur
Gastroenterology Associates of Pensacola, P.A., Pensacola
Care Access, Orlando
University of Miami Crohn's and Colitis Center, Miami
Valencia Medical and Research Center, Miami
I.H.S Health LLC, Kissimmee
Avant Research Associates LLC, Huntsville
Galen Medical Group, Chattanooga
Optimed Research, LTD, Columbus
Communal Enterprise I.I.Mechnykov Dnipropetrovsk Regional Clinical Hospital of Dnipropetrovsk Regional Counsil, cont., Dnipro
Medical Center of Limited Liability Company Gastroenterology Center IBD TEAM, Zaporizhzhya
Communal Non-commercial Enterprise Regional Clinical Hospital of Ivano-Frankivsk Regional Council, Ivano-Frankivsk
Biopharma Informatics, LLC, Houston
LinQ Research, LLC, Pearland
Victoria Gastroenterology, Victoria
Southern Star Research Institute, LLC, San Antonio
Avant Research Associates, LLC, Austin
Care Access Research, Salt Lake City, Salt Lake City
California Medical Research Associates, Inc., Northridge
Allameh Medical Corporation, Mission Viejo
Om Research LLC, Lancaster
Clinical Research of California, Walnut Creek
"Medical Center 'Ok!Clinic+' of Copmany with limited liability International institue of Clinical Research", Kyiv
"Clinical Hospital Feofaniya of State Management of Affairs, Center of Gastroenterology and Endocrinology", Kyiv
Communal Non-commercial Enterprise of Kyiv Regional Council Kyiv Regional Hospital, Department of Therapy, Kyiv
Lead Sponsor
Landos Biopharma Inc.
INDUSTRY